Sandoz Group AG (SWX: SDZ)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
39.87
+0.14 (0.35%)
Nov 20, 2024, 5:30 PM CET
56.11%
Market Cap 17.49B
Revenue (ttm) 9.09B
Net Income (ttm) -7.19M
Shares Out 438.72M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE 14.04
Dividend 0.45 (1.13%)
Ex-Dividend Date n/a
Volume 732,946
Open 40.00
Previous Close 39.73
Day's Range 39.69 - 40.50
52-Week Range 25.01 - 41.16
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 5, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Sector Healthcare
Founded 1886
Employees 22,633
Stock Exchange SIX Swiss Exchange
Ticker Symbol SDZ
Full Company Profile

Financial Performance

In 2023, Sandoz Group AG's revenue was $9.98 billion, an increase of 7.23% compared to the previous year's $9.31 billion. Earnings were $77.00 million, a decrease of -90.92%.

Financial numbers in USD Financial Statements

News

Sandoz Group: Moving To A 'Hold' After A 50% Move

Sandoz Group's stock has surged nearly 50% since my last article, driven by strong performance in the generics and biosimilars sector. Read more here.

2 months ago - Seeking Alpha

Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...

Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance

3 months ago - GuruFocus

Half Year 2024 Sandoz Group AG Earnings Call Transcript

Half Year 2024 Sandoz Group AG Earnings Call Transcript

3 months ago - GuruFocus

Won't see major development in weight loss indication drugs in EU or U.S. until 2030, Sandoz CEO says

Richard Saynor, CEO of Sandoz, discusses the firm's half-year results and shares his outlook for innovation in the weight loss drug market.

3 months ago - CNBC

Generic weight-loss drugs? They’re coming — eventually, executive says

Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.

3 months ago - MarketWatch